 |
|
Bariatric Surgery
A Systematic Review and Meta-analysis
Henry Buchwald, MD, PhD;
Yoav Avidor, MD;
Eugene Braunwald, MD;
Michael D. Jensen, MD;
Walter Pories, MD;
Kyle Fahrbach, PhD;
Karen Schoelles, MD
JAMA. 2004;292:1724-1737.
ABSTRACT
| |
Context About 5% of the US population is morbidly obese. This disease remains largely refractory to diet and drug therapy, but generally responds well to bariatric surgery.
Objective To determine the impact of bariatric surgery on weight loss, operative mortality outcome, and 4 obesity comorbidities (diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea).
Data Sources and Study Selection Electronic literature search of MEDLINE, Current Contents, and the Cochrane Library databases plus manual reference checks of all articles on bariatric surgery published in the English language between 1990 and 2003. Two levels of screening were used on 2738 citations.
Data Extraction A total of 136 fully extracted studies, which included 91 overlapping patient populations (kin studies), were included for a total of 22 094 patients. Nineteen percent of the patients were men and 72.6% were women, with a mean age of 39 years (range, 16-64 years). Sex was not reported for 1537 patients (8%). The baseline mean body mass index for 16 944 patients was 46.9 (range, 32.3-68.8).
Data Synthesis A random effects model was used in the meta-analysis. The mean (95% confidence interval) percentage of excess weight loss was 61.2% (58.1%-64.4%) for all patients; 47.5% (40.7%-54.2%) for patients who underwent gastric banding; 61.6% (56.7%-66.5%), gastric bypass; 68.2% (61.5%-74.8%), gastroplasty; and 70.1% (66.3%-73.9%), biliopancreatic diversion or duodenal switch. Operative mortality ( 30 days) in the extracted studies was 0.1% for the purely restrictive procedures, 0.5% for gastric bypass, and 1.1% for biliopancreatic diversion or duodenal switch. Diabetes was completely resolved in 76.8% of patients and resolved or improved in 86.0%. Hyperlipidemia improved in 70% or more of patients. Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients.
Conclusions Effective weight loss was achieved in morbidly obese patients after undergoing bariatric surgery. A substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement.
INTRODUCTION
The world epidemic of overweight (body mass index [BMI], calculated as weight in kilograms divided by the square of the height in meters,  25) and obesity (BMI 30) is estimated to encompass about 1.7 billion individuals,1-3 and the percentage of overweight adults is highest in the United States.4-7 Approximately two thirds of individuals living in the United States are overweight, and of those, almost half are obese.7 The BMI subgroups experiencing the most rapid growth are 35 or higher (23 million) and 40 or higher (8 million).8-9
The rise in the prevalence of obesity is associated with increases in the prevalence of obesity comorbidities (eg, type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, back and lower extremity weight-bearing degenerative problems, several forms of cancer, depression, etc).10-12 These comorbidities are responsible for more than 2.5 million deaths per year worldwide.10 The loss of life expectancy due to obesity is profound—in comparison with a normal-weight individual, a 25-year-old morbidly obese man has a 22% reduction in expected remaining lifespan, representing an approximate loss of 12 years of life.13
Unfortunately, diet therapy, with and without support organizations, is relatively ineffective in treating obesity in the long term.14-15 There are currently no truly effective pharmaceutical agents to treat obesity, especially morbid obesity.14-15 In 1991, the National Institutes of Health established guidelines for the surgical therapy of morbid obesity (BMI 40 or BMI 35 in the presence of significant comorbidities), now referred to as bariatric surgery.16
The literature on postoperative weight loss and the problems associated with various bariatric surgical procedures is extensive and has been summarized elsewhere.17 The literature with respect to comorbidity outcomes of bariatric surgery is also extensive, but has not been systematically reviewed and subjected to meta-analysis. We have conducted a systematic review of published observational and interventional trials that focus on bariatric surgery. The subsequent meta-analysis has concentrated on the impact of bariatric surgery on 4 selected obesity comorbidities: diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea. For consistency, meta-analyses of weight loss outcomes were confined to the studies qualifying for the categories selected for assessment.
METHODS
We used a comprehensive and current database to catalog the bariatric surgery literature. The catalog was developed as an online, navigable research adjunct. The evidence database for the catalog was assembled using established systematic review methods.18-19
The main objectives of this study were to analyze the impact of bariatric surgery on diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea, as well as on health care economics and disease impact; to analyze weight reduction efficacy outcomes in the studies selected for the comorbid conditions; and to summarize operative mortality outcomes.
Data Sources
A broad search of the English-language literature was performed incorporating both electronic and manual components. The electronic search was performed using MEDLINE, Current Contents, and the Cochrane Library databases. MEDLINE (1990-2003, cutoff date June 5, 2003) was searched using the following search terms: obesity/surgery, gastric bypass, gastroplasty, bariatric, gastric banding, "anastomosis, Roux-en-Y," biliopancreatic diversion (including duodenal switch), or jejunoileal bypass. Prior to 1990, the literature offered little to no clinical data on the impact of bariatric surgery weight loss on diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea. The complete bibliography of accepted and rejected studies is available by request to the corresponding author.
Two strategies were used to identify recently published articles that may not have been indexed on MEDLINE by the search cutoff date. First, a search was performed that included a keyword search for the prior 6 months with no limit. Next, Current Contents was searched for the prior year using an analogous approach. Finally, manual reference checks of accepted papers in recent reviews (within the past 2 years) were performed to supplement the above electronic searches. The cutoff date for the retrieval of articles from libraries was July 2003.
Literature Screening and Catalog Construction
Study selection was accomplished through 2 levels of study screening. At level 1 screening, abstracts were reviewed for the following exclusion criteria: publication of abstracts only, case reports, letters, comments, and reviews; animal or in vitro studies; fewer than 10 patients in the study; follow-up of less than 30 days; languages other than English; no surgical intervention for obesity; and intragastric balloon therapy (experimental device).
Full articles were then obtained for all studies accepted at level 1 and for any citations for which a determination could not be made from the abstract. For level 2 screening, inclusion required that the studies dealt with at least 1 of the following categories of information: surgical outcomes (including efficacy and/or safety), guidelines, health care economics, or disease impact (utilization [eg, hospital length of stay for bariatric surgery and readmissions] and quality of life).
Study Selection for Data Extraction
For inclusion in the subset of studies for data extraction, the screened studies had to report outcomes for one or more of the following comorbid conditions: diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea, or on health care economics. Extracted studies could be of any design, published from 1990 to 2003, and had to have enrolled at least 10 patients undergoing bariatric surgery. All outcomes were preferentially extracted at the time points for which the comorbidity outcomes were available or the latest time point available for follow-up of at least 50% of the population. In studies reporting morbidity improvement, an effort was made to determine both the number of patients evaluated and the time point of evaluation. In some studies, however, the number of patients with a condition at baseline was the only denominator available. Time points for comorbidity improvement were imputed for some studies based on the time point at which other outcomes were reported (principally weight loss). Kin relationships, defined as multiple publications describing the same or overlapping series of patients, were identified and entered into our catalog only once to avoid the double counting of patients.
Definitions
Surgical Procedures. Surgical procedures were grouped into the following categories: gastric banding (including adjustable and nonadjustable bands), gastric bypass (principally Roux-en-Y variations), gastroplasty (principally vertical banded gastroplasty), biliopancreatic diversion or duodenal switch (including a variety of modifications), and mixed and other (biliary intestinal bypass, ileogastrostomy, jejunoileal bypass, and unspecified bariatric). Procedures that included a gastric bypass component (eg, gastroplasty with gastric bypass, biliopancreatic diversion with gastric bypass, and banding with gastric bypass) were classified as gastric bypass surgery. The history and evolution of the procedures discussed, by open and laparoscopic techniques, have been described.20
Results are reported individually for gastric banding, gastric bypass, gastroplasty, and biliopancreatic diversion or duodenal switch procedure groups, as well as for the total population, which included gastric banding, gastric bypass, gastroplasty, and biliopancreatic diversion or duodenal switch, plus mixed groups and other less common bariatric surgery procedures (biliary intestinal bypass, ileogastrostomy, jejunoileal bypass, and unspecified bariatric surgery).
Resolved and Resolved or Improved. Outcomes of the selected comorbidities were grouped into categories of resolved and resolved or improved. For the calculation of the percentage resolved, we included those studies reporting the number of patients in which comorbid conditions disappeared or no longer required therapy. We preferentially extracted the number of patients evaluated as the denominator wherever possible. For the calculation of the percentage resolved or improved, we included studies reporting numbers of patients in both of these 2 categories (in which case, the 2 were summed), as well as studies that only used the term improved, but not the studies reporting only resolution. Consequently, the percentage resolved or improved may be lower than the percentage deemed resolved due to different study cohorts and, therefore, different denominators for the percentage calculations. Improved in lipid disorders was defined as normalization of laboratory values or the reduction or discontinuation of medical therapy.
Weight Loss. Weight loss is reported as the mean percentage of excess weight loss, which is the standard in the bariatric surgery nomenclature. This calculation is derived from the formula: percentage of excess weight loss = (weight loss/excess weight) x 100, where excess weight = total preoperative weight – ideal weight. Changes in absolute weight (kilograms), BMI, and percentage of initial weight are also reported when appropriate.
Safety Data. Operative mortality (30 days) is reported. Complication rates were difficult to catalog because they were variably reported, dependent on duration of follow-up, and were procedure specific, as well as a function of open compared with laparoscopic technique. They are not included in this article.
Statistical Analysis
Analyses were performed only on the data from the studies in the data extraction subset. Study, patient, and treatment-level data were summarized using basic descriptive statistics (simple counts and means). The number of patients enrolled or randomized was used in the calculation of study and patient demographics.
Efficacy outcomes of interest were synthesized via meta-analytic pooling of similar surgery group results across studies with stratification by the type of surgery. In addition, meta-analysis of within-study surgery effects on weight loss and diabetes-related outcomes were stratified by studies with extractable outcomes for a general population compared with subgroups of patients with diabetes or impaired glucose tolerance.
Meta-analyses of all efficacy outcomes were conducted using a random-effects model, estimated by using the restricted maximum likelihood method.21-22 Efficacy outcomes included both proportions (eg, response rates) and raw mean before and after changes (eg, absolute weight changes). The random-effects model meta-analyses take into account both study sample size and the estimate of between-study variation (ie, study heterogeneity) when weighting study effects. Meta-analytic means and mean changes are expressed with 95% confidence intervals (CIs).
Weighted means (ie, weighting results by sample size) were calculated for all studies for a given outcome to provide a non–meta-analytic comparison for each result. A drawback of the weighted means analysis is that it ignores between-study variations, providing a result similar to that found by a fixed-effects analysis. There are, however, positive aspects of the use of weighted means. In the analysis of continuous data, some outcomes had exceedingly wide fluctuations in within-study variation, allowing certain studies of the same size to be weighted quite differently.
All calculations were performed using SAS (version 8.1, SAS Institute Inc, Cary, NC) and SPSS (version 11.0, SPSS Inc, Chicago, Ill) statistical software.
RESULTS
Data Retrieval
A flow diagram outlining the systematic review process is provided (Figure). The initial literature review identified 2738 citations for screening. Of these, 1772 were rejected after reviewing the abstracts and 5 publications could not be retrieved prior to the retrieval cutoff date of July 18, 2003. Of the remaining 961 articles, 253 did not meet inclusion criteria for the catalog, and 572 studies met inclusion criteria only for the catalog but not for further analysis. Therefore, 136 fully extracted primary studies (for which there were 91 "kin" or linked publications) were available for meta-analysis.
|
|
|
|
Figure. Study Attrition Diagram
Asterisk indicates 2 health care economics studies without efficacy or safety data are included in the 136 primary studies.
|
|
|
Decisions about relationships among publications were made to maximize information on the comorbidities of interest without double counting patients. Several important studies had numerous kin publications. Outcomes of interest were typically presented in the more recently published articles in which longer periods of follow-up were reported for some or all of the patients. On the other hand, in some large studies only small subgroups of patients with outcomes relevant to the comorbidities of interest were reported and these articles were again dealt with to avoid counting patients more than once.
There were a total of 136 studies, within which there were 179 treatment groups and 22 094 patients either enrolled or analyzable in the data set, including those in comparator control groups. Health care economic outcomes were varied and not amenable to meta-analysis. We did, however, include the weight loss efficacy and operative mortality data from those studies in these respective analyses.
Study Characteristics
After excluding 2 health care economics studies with no weight loss or mortality data, 134 studies were extracted. Fifty-six of the extracted studies were based in North America, 58 in Europe, and 20 were conducted in other locations throughout the world (Australia, New Zealand, South America, Japan, Israel, Saudi Arabia, and Taiwan) (Table 1 and Table 2). Included were 5 randomized controlled trials, 28 nonrandomized controlled trials or series with comparison groups, and 101 uncontrolled case series. The majority of studies were conducted at single centers (n = 126) and only a few were multicenter studies (n = 5). At least 1 categorical outcome of interest (eg, proportion of patients with resolution or improvement in diabetes, hyperlipidemia, hypertension, or obstructive sleep apnea) or 1 continuous outcome of interest (change in a laboratory or physiological measure) was reported by each of the extracted studies.
|
|
|
|
Table 1. Characteristics of Total Population and Gastric Banding and Gastric Bypass Studies*
|
|
|
|
|
|
|
Table 2. Characteristics of Gastroplasty and Biliopancreatic Diversion or Duodenal Switch Studies*
|
|
|
Patient Characteristics
In studies reporting sex (150 treatment groups), 19.4% (n = 3769) of patients were men and 72.6% (n = 14 082) were women (Table 3). Sex was not reported for 1537 patients (8%). The overall mean age was 38.97 years (range, 16.20-63.60 years) in studies for which this was reported. The BMI for 16 944 patients at baseline was 46.85 (range, 32.30-68.80). Patient characteristics such as mean age and BMI at baseline were relatively similar across surgical procedure types.
|
|
|
|
Table 3. Patient Characteristics*
|
|
|
Weight Loss
Given the emphasis on comorbidities, weight loss efficacy outcomes were preferentially extracted at time points for which comorbidity changes were reported. In addition, whenever possible, outcome time points representing at least 50% of the patient population undergoing surgery were used.
Substantial weight reduction was observed in this study set by both meta-analytic techniques and simple pooling across studies using weighted means (Table 4). The mean (95% CI) percentage of excess weight loss by meta-analysis at the outcome time point for which comorbidities were assessed was 47.5% (40.7%-54.2%) for gastric banding, 61.6% (56.7%-66.5%) for gastric bypass, 68.2% (61.5%-74.8%) for gastroplasty, and 70.1% (66.3%-73.9%) for biliopancreatic diversion or duodenal switch. The overall percentage of excess weight loss for 10 172 patients for all surgery types was 61.2% (95% CI, 58.1%-64.4%). Although less common, weight loss outcomes were also reported as a decrease in BMI (mean [95% CI], 14.2 [13.3-15.1] in 8232 patients) and a decrease in absolute weight (mean [95% CI], 39.7 kg [37.2-42.2 kg] in 7588 patients). In most cases, weight loss outcomes did not differ significantly for assessments at 2 years or less compared with those at more than 2 years. All of the weight loss reductions reported in Table 4 are significant at the P<.001 level.
|
|
|
|
Table 4. Efficacy Outcomes for Weight Reduction*
|
|
|
Operative Mortality
Operative mortality—mortality at 30 or less days—was 0.1% for the purely restrictive procedures (2297 patients undergoing banding and 749 patients undergoing gastroplasty), 0.5% in 5644 patients undergoing gastric bypass procedures, and 1.1% in 3030 patients undergoing biliopancreatic diversion or duodenal switch procedures.
Comorbidity Outcomes
Diabetes. When defined as the ability to discontinue all diabetes-related medications and maintain blood glucose levels within the normal range, strong evidence for improvement in type 2 diabetes and impaired glucose tolerance was found across all the surgery types. Within studies reporting resolution of diabetes, 1417 (76.8% [meta-analytic mean, 76.8%; 95% CI, 70.7%-82.9%]) of 1846 patients experienced complete resolution. Within studies reporting both resolution and improvement or only improvement of diabetes, 414 (85.4% [meta-analytic mean, 86.0%; 95% CI, 78.4%-93.7%]) of 485 patients experienced resolution or improvement of diabetes. The changes in glycosylated hemoglobin (HbA1c), fasting glucose, and fasting insulin are also reported in Table 5 and Table 6.
|
|
|
|
Table 5. Efficacy for Improvement in Diabetes-Related Outcomes for All Patients
|
|
|
|
|
|
|
Table 6. Efficacy for Improvement in Diabetes-Related Outcomes for Diabetic and Glucose-Intolerant Patients*
|
|
|
In patients selected for diabetes or impaired glucose tolerance at baseline, the mean change in percentage of excess weight loss was 57.25% (95% CI, 46.21%-68.30%) and the reduction in the BMI was 14.03 (95% CI, 10.77-17.30), both of which are close to the values for unselected populations. Reductions in HbA1c and fasting glucose levels were much greater in groups selected for baseline diabetes or impaired glucose tolerance. The reduction in fasting glucose levels was significantly different for the total diabetic population (mean change, 71.53 mg/dL; 95% CI, 49.37-93.69 mg/dL [3.97 mmol/L; 95% CI, 2.74-5.20 mmol/L]; n = 296 by meta-analysis) compared with unselected populations (mean change, 13.33 mg/dL; 95% CI, 10.81-15.86 mg/dL [0.74 mmol/L; 95% CI, 0.60-0.88 mmol/L]; n = 2092 by meta-analysis).
There was a difference in diabetes outcomes analyzed according to the 4 categories of operative procedures. With respect to diabetes resolution, there was a gradation of effect from 98.9% (95% CI, 96.8%-100%) for biliopancreatic diversion or duodenal switch to 83.7% (95% CI, 77.3%-90.1%) for gastric bypass to 71.6% (95% CI, 55.1%-88.2%) for gastroplasty, and to 47.9% (95% CI, 29.1%-66.7%) for gastric banding. The percentage of patients with diabetes resolved or improved showed different results (Table 5); this variation from the trend solely for diabetes resolved may be due to the far greater number of patients assessed for this variable (n = 1846) compared with the number assessed for the combined variable (n = 485) in the total population.
Hyperlipidemia. By both meta-analysis and by weighted means, the outcome categories of hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia were significantly improved across all surgical procedures (including the mixed and other bariatric surgery groups; Table 7). The percentage of patients improved was typically 70% or higher, with some variation as a function of the measure used and the procedure performed. The maximum improvements in hyperlipidemia by meta-analysis occurred with the biliopancreatic diversion or duodenal switch procedure (99.1%; 95% CI, 97.6%-100%) and with gastric bypass (96.9%; 95% CI, 93.6%-100%).
|
|
|
|
Table 7. Efficacy for Improvement in Hyperlipidemia by Surgical Procedure
|
|
|
In the total population, meta-analysis of the continuous measures demonstrated a significant decrease in total cholesterol level (mean change, 33.20 mg/dL; 95% CI, 23.17-43.63 mg/dL [0.86 mmol/L; 95% CI, 0.60-1.13 mmol/L]; n = 2573), low-density lipoprotein cholesterol level (mean change, 29.34 mg/dL; 95% CI, 17.76-40.93 mg/dL [0.76 mmol/L; 95% CI, 0.46-1.06 mmol/L]; n = 879), and level of triglycerides (mean change, 79.65 mg/dL; 95% CI, 64.60-95.58 mg/dL [0.90 mmol/L; 95% CI, 0.73-1.08 mmol/L]; n = 2149). While there was not a significant increase in high-density lipoprotein cholesterol level in the total population, significant improvements were seen with gastric banding (mean change, 4.63 mg/dL; 95% CI, 1.54-7.72 mg/dL [0.12 mmol/L; 95% CI 0.04-0.20 mmol/L]; n = 623) and with gastroplasty (mean change, 5.02 mg/dL; 95% CI, 0.77-9.27 mg/dL [0.13 mmol/L; 95% CI, 0.02-0.24 mmol/L]; n = 253).
Hypertension. By both meta-analysis and by weighted proportions, hypertension significantly improved in the total patient population and across all surgical procedures (Table 8). The percentage of patients in the total population whose hypertension resolved was 61.7% (95% CI, 55.6%-67.8%). The percentage of patients in the total population whose hypertension resolved or improved was 78.5% (95% CI, 70.8%-86.1%). The rank order of efficacy among the surgical groups was variable for both resolution and resolution or improvement.
|
|
|
|
Table 8. Efficacy for Improvement in Hypertension and Obstructive Sleep Apnea by Surgical Procedure
|
|
|
Obstructive Sleep Apnea. Diagnoses of sleep apnea, sleep-disordered breathing, and pickwickian syndrome were combined as representative of obstructive sleep apnea. By both meta-analysis and by weighted means, the combined outcome category of obstructive sleep apnea was significantly improved in the total patient population group and in each surgical procedure group (Table 8). The percentage of patients in the total population whose obstructive sleep apnea resolved was 85.7% (95% CI, 79.2%-92.2%). The percentage of patients in the total population whose obstructive sleep apnea resolved or improved was 83.6% (95% CI, 71.8%-95.4%).
Evidence for changes in obstructive sleep apnea was primarily available for gastric bypass patients. This was particularly so for the continuous objective variable of apneas or hypopneas per hour (4 available studies), which decreased by 33.85 per hour (95% CI, 17.47-50.23 per hour) in the total population, including 2 gastric bypass groups.
Randomized Controlled Trials
Data from the 5 randomized controlled trials were examined separately for weight loss and, when feasible, for the impact on mortality for 30 or fewer days and the 4 comorbidities (Table 9). These outcomes were within the range of values and the trends found for the overall meta-analysis.
|
|
|
|
Table 9. Surgical Outcomes for the 5 Randomized Controlled Trials*
|
|
|
COMMENT
Bariatric surgery in morbidly obese individuals reverses, eliminates, or significantly ameliorates diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea. These benefits occur in the majority of patients who undergo surgery.
With respect to type 2 diabetes, more than three quarters of the patients experienced complete resolution of their diabetes following bariatric surgery. Of those patients not experiencing complete resolution, more than half showed demonstrable improvement. Thus, about 85% of patients with diabetes experienced improvement in their diabetes course after bariatric surgery.
A landmark article on bariatric surgery was published in 1995.28 Provocatively titled, "Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus," this article inspired more than 30 studies demonstrating resolution or marked improvement in type 2 diabetes after bariatric surgery. Two recently published series (after our cut-off date for inclusion) by Schauer et al29 and Sugerman et al30 report almost identical rates of resolution as our meta-analysis, 83% and 86%, respectively. In addition, at 2-year follow-up, a 60% decrease in plasma insulin and a 20% decrease in the plasma glucose were seen in the surgical weight loss group in the Swedish Obesity Subjects study.31 The control group at 2 years had a 3.7-fold higher risk of diabetes onset.
Resolution of diabetes often occurred days following bariatric surgery, even before marked weight loss was achieved.28 Resolution of diabetes was more prevalent following the predominantly malabsorptive procedures (biliopancreatic diversion or duodenal switch) and the mixed malabsorptive/restrictive gastric bypass in contrast to the purely restrictive gastroplasty and gastric banding procedures. In addition, there appeared to be a gradation of diabetes resolution as a function of the operative procedure itself: 98.9% for biliopancreatic diversion or duodenal switch, 83.7% for gastric bypass, 71.6% for gastroplasty, and 47.9% for gastric banding.
The putative extent and time relationships of the different operative procedures to diabetes resolution or improvement after bariatric surgery may be related to some of the changes in the gut-related hormones. The hormonal milieu, or the relative balance of foregut mediators, is differently affected when the distal stomach is bypassed, or a partial gastrectomy is performed, and the enteric contents are separated from the biliopancreatic stream in the upper small intestinal tract. The study of the impact of the various bariatric procedures on leptin, ghrelin, resistin, acylation-stimulating protein, adiponectin, entroglucagon, cholecystokinin, and other gastrointestinal satiety mediators is receiving increasing attention.32-36
Current metabolic studies of patients with diabetes undergoing bariatric surgery have shown a recovery of acute insulin response37; significant decreases of inflammatory indicators (C-reactive protein and interleukin 6)38; improvement in insulin sensitivity correlated with increases in plasma adiponectin32, 39; significant changes in the enteroglucagon response to glucose40; significant reduction in ghrelin levels following gastric bypass41 but not gastric banding42; and significant improvement in beta cell function following gastric banding.43
Considerable attention recently has focused on the Swedish Obesity Subjects study, in which 2010 patients after gastric bypass, gastroplasty, or gastric banding were compared with 2037 matched-pair controls who underwent conventional nonoperative obesity management. After 2 years, the incidence of hyperlipidemia was lower by 10-fold in the surgical weight loss group compared with the control group.31 Similar findings have been reported by others.44-47 In 1990, the Program on the Surgical Control of the Hyperlipidemias reported marked reductions in the levels of total (23%) and low-density lipoprotein cholesterol (38%), in association with increases in high-density lipoprotein cholesterol (4%) after a surgical distal ileal malabsorptive procedure.48 In the current meta-analysis, the improvement in hyperlipidemia also was more prevalent with the malabsorptive procedures.
Resolution or improvement of hypertension by weight reduction is well-known. Even a modest weight loss (eg, 10%) can lower blood pressure significantly. As a generalization, a decrease of 1% in body weight will decrease systolic blood pressure by 1 mm Hg and diastolic blood pressure by 2 mm Hg.49-51 The bariatric surgery literature extracted for this analysis is replete with reports of the resolution or improvement in hypertension postoperatively. This reduction in blood pressure, in distinction to the effect of weight loss on type 2 diabetes and hyperlipidemia, seems to be independent of the operative procedure performed.
In the current analysis, improvement in obstructive sleep apnea was dramatic—in the 80% or higher range. The extracted bariatric surgery literature is quite prolific on this subject. In association with the clinical findings, improvements in oxygen saturation, decreases in arterial carbon dioxide, and increases in arterial oxygen content have been demonstrated.52-53 These favorable physiological changes in the blood contents, which in turn affect the neurological pathways and cerebral centers responsible for respiration, are primarily the result of an increase in diaphragmatic excursion. This increase is brought about by a reduction in intra-abdominal pressure after successful bariatric surgery.54-55
Reversal of or marked improvement in diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, and obesity itself, should markedly increase life expectancy. A large, prospective, observational study, which controlled for unintentional weight loss and for smoking, of 43 457 women had a 12-year follow-up and showed that a weight loss of at least 9 kg was associated with a 53% reduction in all obesity-related deaths.56 A growing amount of evidence relates increased longevity with successful bariatric surgery. The Swedish Obesity Subjects study in diabetic patients has shown an 80% decrease in the annual mortality in the surgical weight loss group.31 Specifically, the obese diabetic patients in the surgical group had a 9% mortality at 9 years, whereas, the control group had a 28% mortality, with most deaths related to cardiovascular disease. In a comparable study, MacDonald et al57 reported that diabetic patients treated with an oral hypoglycemic had a 4.5% mortality rate for every 9 years of follow-up compared with a 1% mortality rate in diabetic patients who underwent gastric bypass. Christou et al58 demonstrated that weight-loss surgery in 1035 patients compared with 5746 controls with a 5-year follow-up reduced the relative risk of death by 89% (95% CI, 73%-96%), with an absolute mortality reduction of 5.49% (P<.001).
All therapeutic interventions need to have efficacy balanced against risk. In such an assessment, bariatric surgery does well. The operative 30-day mortality rates of 0.1% for the restrictive procedures, 0.5% for gastric bypass, and 1.1% for biliopancreatic diversion or duodenal switch compare favorably with the accepted operative mortality rates for other major surgical procedures.
The heterogeneity of the immediate postoperative and long-term morbidity data did not allow for meta-analysis. However, although these data are diverse, operation-specific reports of adverse outcomes are available for gastric banding,59-61 gastric bypass,28, 30, 62 gastroplasty,23, 63-64 and biliopancreatic diversion or duodenal switch.65-67
Even after accounting for the pain and anxiety of surgery, the inconveniences of dietary restrictions, and possible complications including reoperation, quality of life should improve for the majority of bariatric surgery patients. A weight loss often in excess of 45 kg, relief from fatal comorbid diseases, improved appearance, and improved social and economic opportunities should markedly enhance quality of life and several studies support this contention.68-73 The perception of well-being, social function, body self-image, self-confidence, ability to interact with others, and time spent in recreational and physical activities increases after successful bariatric surgery. Productivity and economic opportunities are enhanced, including new employment and more lucrative employment.
In summary, in addition to the effective weight loss achieved by patients undergoing bariatric surgical procedures, a substantial majority of patients with diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea experienced complete resolution or improvement of their comorbid condition.
AUTHOR INFORMATION
Corresponding Author: Henry Buchwald, MD, PhD, University of Minnesota, 420 Delaware St SE, MMC 290, Minneapolis, MN 55455 (buchw001{at}umn.edu).
Author Contributions: Dr Buchwald had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Buchwald, Avidor, Pories, Fahrbach, Schoelles.
Acquisition of data: Buchwald, Avidor, Pories, Schoelles.
Analysis and interpretation of data: Buchwald, Avidor, Braunwald, Jensen, Pories, Fahrbach, Schoelles.
Drafting of the manuscript: Buchwald, Avidor, Pories, Fahrbach.
Critical revision of the manuscript for important intellectual content: Buchwald, Avidor, Braunwald, Jensen, Pories, Schoelles.
Statistical expertise: Buchwald, Fahrbach.
Obtained funding: Avidor.
Administrative, technical, or material support: Buchwald, Avidor, Jensen, Pories, Schoelles.
Study supervision: Buchwald, Avidor, Schoelles.
Funding/Support: Sponsored by Ethicon Endo-Surgery Inc, a Johnson & Johnson Company, Cincinnati, Ohio.
Role of the Sponsor: Ethicon Endo-Surgery Inc, paid for the services of MetaWorks (Medford, Mass). The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.
Acknowledgment: We thank the following individuals at MetaWorks Inc, who were instrumental in performing the literature search and subsequent preparation of data and meta-analysis: Diana Frame, MEM, Catherine Cella, BA, and Rhonda Estok, RN, CNOR. We also thank Jane Buchwald, MA, MEDWRITE Medical Communications, Minneapolis, Minn, for performing substantive editing of the manuscript.
Financial Disclosures: Drs Buchwald and Jensen are consultants to Ethicon Endo-Surgery Inc.
Author Affiliations: Department of Surgery, University of Minnesota, Minneapolis (Dr Buchwald); Ethicon Endo-Surgery Inc, a Johnson & Johnson company, Cincinnati, Ohio (Dr Avidor); Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (Dr Braunwald); Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Dr Jensen); Department of Surgery, East Carolina University School of Medicine, Greenville, NC (Dr Pories); and MetaWorks Inc, Medford, Mass (Drs Fahrbach and Schoelles).
REFERENCES
| |
1. Deitel M. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg. 2003;13:329-330.
FULL TEXT
|
ISI
| PUBMED
2. International Obesity Task Force. Call for obesity review as overweight numbers reach 1.7 billion [press release]. London, England: International Obesity Task Force; March 17, 2003. Available at: http://www.iotf.org/media/iotfmar17.htm. Accessed September 12, 2004.
3. Worldwatch Institute Web site. Available at: http://www.worldwatch.org. Accessed September 9, 2002.
4. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39-47.
FULL TEXT
|
ISI
| PUBMED
5. Mokdad AH, Serdula MK, Dietz WH, Bowman BS, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
FREE FULL TEXT
6. Monteforte MJ, Torkelson CM. Bariatric surgery for morbid obesity. Obes Surg. 2000;10:391-401.
FULL TEXT
|
ISI
| PUBMED
7. National Center for Health Statistics NHANES IV Report. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99.htm Accessed September 9, 2002.
8. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
FREE FULL TEXT
9. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med. 2003;163:2146-2148.
FREE FULL TEXT
10. World Health Organization. World Health Report 2002. Available at: http://www.iotf.org. Accessed January 13, 2004.
11. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
FREE FULL TEXT
12. Overweight, obesity, and health risk: National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med. 2000;160:898-904.
FREE FULL TEXT
13. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187-193.
FREE FULL TEXT
14. North American Association for the Study of Obesity and the National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, Md: National Institutes of Health; 2000. NIH publication 00-4084.
15. North American Association for the Study of Obesity (NAASO) and the National Heart. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md: National Institutes of Health; 1998. NIH publication 98-4083.
16. National Institutes of Health Consensus Development Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115:956-961.
17. Buchwald H. A bariatric surgery algorithm. Obes Surg. 2002;12:733-746.
FULL TEXT
|
ISI
| PUBMED
18. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126:376-380.
FREE FULL TEXT
19. Mulrow CD, ed, Oxman AD, ed. Cochrane Collaboration Handbook. Oxford, England: Cochrane Library, Update Software; 1997;issue 1.
20. Buchwald H, Buchwald JN. Evolution of operative procedures for the management of morbid obesity: 1950-2000. Obes Surg. 2002;12:705-717.
FULL TEXT
|
ISI
| PUBMED
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
FULL TEXT
|
ISI
| PUBMED
22. Hedges L, Olkin I. Statistical Methods for Meta-analysis. Orlando, Fla: Academic Press; 1985:230-257.
23. Ashy AR, Merdad AA. A prospective study comparing vertical banded gastroplasty versus laparoscopic adjustable gastric banding in the treatment of morbid and super-obesity. Int Surg. 1998;83:108-110.
ISI
| PUBMED
24. Hall JC, Watts JM, O'Brien PE, et al. Gastric surgery for morbid obesity: the Adelaide Study. Ann Surg. 1990;211:419-427.
ISI
| PUBMED
25. Mingrone G, Greco AV, Giancaterini A, Scarfone A, Castagneto M, Pugeat M. Sex hormone-binding globulin levels and cardiovascular risk factors in morbidly obese subjects before and after weight reduction induced by diet or malabsorptive surgery. Atherosclerosis. 2002;161:455-462.
FULL TEXT
|
ISI
| PUBMED
26. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg. 2001;234:279-289.
FULL TEXT
|
ISI
| PUBMED
27. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord. 2002;26:193-199.
FULL TEXT
|
ISI
| PUBMED
28. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-352.
ISI
| PUBMED
29. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-484.
ISI
| PUBMED
30. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237:751-756.
FULL TEXT
|
ISI
| PUBMED
31. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7:477-484.
ISI
| PUBMED
32. Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594-1602.
FREE FULL TEXT
33. Yannakoulia M, Yiannakouris N, Blüher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730-1736.
FREE FULL TEXT
34. Pories WJ, Albrecht RJ. Etiology of type 2 diabetes mellitus: role of the foregut. World J Surg. 2001;25:527-531.
FULL TEXT
|
ISI
| PUBMED
35. Hickey MS, Pories WJ, MacDonald KG, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?. Ann Surg. 1998;227:637-644.
FULL TEXT
|
ISI
| PUBMED
36. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11.
ISI
| PUBMED
37. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute insulin response in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52:1098-1103.
FREE FULL TEXT
38. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042-1047.
FREE FULL TEXT
39. Geloneze B, Pereira JA, Pareja JC, et al. Circulating Concentrations of Adiponectin Increase in Parallel With Enhancement of Insulin Sensitivity During Weight Loss in Humans. Alexandria, Va: American Diabetes Association; 2003. Abstract 1707-P.
40. Kellum JM, Kuemmerle JF, O’Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763-770.
ISI
| PUBMED
41. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.
FREE FULL TEXT
42. Hanusch-Enserer U, Brabant G. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding. N Engl J Med. 2003;348:2159-2160.
FREE FULL TEXT
43. Dixon JB, Dixon AF, O’Brien PE. Improvement in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Diabet Med. 2003;20:127-134.
FULL TEXT
|
ISI
| PUBMED
44. Brolin RE, Kenler HA, Wilson AC, Kuo PT, Cody RP. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obes. 1990;14:939-950.
ISI
| PUBMED
45. Buffington CK, Cowan GSM, Hughes TA, Smith H. Significant changes in the lipid-lipoprotein status of premenopausal morbidly obese females following gastric bypass surgery. Obes Surg. 1994;4:328-335.
FULL TEXT
|
ISI
| PUBMED
46. Cowan GS Jr, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998;22:987-992.
FULL TEXT
|
ISI
| PUBMED
47. Gleysteen JJ. Results of surgery: long-term effects on hyperlipidemia. Am J Clin Nutr. 1992;55:591S-593S.
FREE FULL TEXT
48. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
ABSTRACT
49. Dornfeld LP, Maxwell MH, Waks AU, Schroth P, Tuck ML. Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int J Obes. 1985;9:381-389.
ISI
| PUBMED
50. Hypertension Prevention Treatment Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med. 1990;150:153-162.
FREE FULL TEXT
51. Reisin E, Frohlich ED. Effects of weight reduction on arterial pressure. J Chronic Dis. 1982;35:887-891.
FULL TEXT
|
ISI
| PUBMED
52. Rajala R, Partinen M, Sane T, Pelkonen R, Huikuri K, Seppalainen AM. Obstructive sleep apnea syndrome in morbidly obese patients. J Intern Med. 1991;230:125-129.
ISI
| PUBMED
53. Rasheid S, Banasiak M, Gallagher SF, et al. Gastric bypass is an effective treatment for obstructive sleep apnea in patients with clinically significant obesity. Obes Surg. 2003;13:58-61.
FULL TEXT
|
ISI
| PUBMED
54. Sugerman H, Windsor A, Bessos M, Wolfe L. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med. 1997;241:71-79.
FULL TEXT
|
ISI
| PUBMED
55. Weiner P, Walzman J, Weiner M, Rabner M, Magadle R, Zamir D. Influence of excessive weight loss after gastroplasty for morbid obesity on respiratory muscle performance. Thorax. 1998;53:39-42.
ABSTRACT
56. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995;141:1128-1141.
FREE FULL TEXT
57. MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality on non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213-220.
FULL TEXT
| PUBMED
58. Christou NV, Sampalis JS, Lieberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240:416-423.
ISI
| PUBMED
59. Ceelen W, Walder J, Cardon A, et al. Surgical treatment of severe obesity with a low-pressure adjustable gastric band: experimental data and clinical results in 625 patients. Ann Surg. 2003;237:10-16.
FULL TEXT
|
ISI
| PUBMED
60. O'Brien PE, Dixon JB, Brown W, et al. The laparoscopic adjustable gastric band (Lap-Band): a prospective study of medium-term effects on weight, health and quality of life. Obes Surg. 2002;12:652-660.
FULL TEXT
|
ISI
| PUBMED
61. Zinzindohoue F, Chevallier JM, Douard R, et al. Laparoscopic gastric banding: a minimally invasive surgical treatment for morbid obesity: prospective study of 500 consecutive patients. Ann Surg. 2003;237:1-9.
ISI
| PUBMED
62. Smith SC, Edwards CB, Goodman GN. Changes in diabetic management after Roux-en-Y gastric bypass. Obes Surg. 1996;6:345-348.
FULL TEXT
|
ISI
| PUBMED
63. Kalfarentzos F, Dimakopoulos A, Kehagias I, Loukidi A, Mead N. Vertical banded gastroplasty versus standard or distal Roux-en-Y gastric bypass based on specific selection criteria in the morbidly obese: preliminary results. Obes Surg. 1999;9:433-442.
FULL TEXT
|
ISI
| PUBMED
64. Nightengale ML, Sarr MG, Kelly KA, Jensen MD, Zinsmeister AR, Palumbo PJ. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity. Mayo Clin Proc. 1991;66:773-782.
ISI
| PUBMED
65. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998;8:267-282.
FULL TEXT
|
ISI
| PUBMED
66. Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg. 1998;22:947-954.
FULL TEXT
|
ISI
| PUBMED
67. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936-946.
FULL TEXT
|
ISI
| PUBMED
68. Karlsson J, Sjöström L, Sullivan M. Swedish obese subjects (SOS): an intervention study of obesity: two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obes Relat Metab Disord. 1998;22:113-126.
FULL TEXT
|
ISI
| PUBMED
69. Kral JG. The role of surgery in obesity management. Int J Risk Safety Med. 1995;7:111-120.
70. Rand CS, Macgregor AM. Morbidly obese patients’ perceptions of social discrimination before and after surgery for obesity. South Med J. 1990;83:1390-1395.
ISI
| PUBMED
71. van Gemert WG, Adang EMM, Greve JWM, Soeters PB. Quality of life assessment of morbidly obese patients: effect of weight-reducing surgery. Am J Clin Nutr. 1998;67:197-201.
ABSTRACT
72. Dymek MP, LeGrange D, Neven K, Alverdy J. Quality of life and psychosocial adjustment in patients after Roux-en-Y gastric bypass: a brief report. Obes Surg. 2001;11:32-39.
FULL TEXT
|
ISI
| PUBMED
73. Waters GS, Pories WJ, Swanson MS, Meelheim HD, Flickinger EG, May HJ. Long-term studies of mental health after the Greenville gastric bypass operation for morbid obesity. Am J Surg. 1991;161:154-157.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Systematic Review of Bariatric Surgery
and
JAMA. ;293():1726-1726.
FULL TEXT
Systematic Review of Bariatric Surgery
JAMA. ;293():1726-1726.
FULL TEXT
Systematic Review of Bariatric Surgery--Reply
, , , , , , and
JAMA. ;293():1726-1726.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport
Stearns et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2009;297:G950-G957.
ABSTRACT
| FULL TEXT
Diabetes Surgery: A New Approach to an Old Disease
Rubino et al.
Diabetes Care 2009;32:S368-S372.
FULL TEXT
Short-Term Dynamics and Metabolic Impact of Abdominal Fat Depots After Bariatric Surgery
Weiss et al.
Diabetes Care 2009;32:1910-1915.
ABSTRACT
| FULL TEXT
Weight Loss Interventions in Chronic Kidney Disease: A Systematic Review and Meta-analysis
Navaneethan et al.
CJASN 2009;4:1565-1574.
ABSTRACT
| FULL TEXT
A 52-Year-Old Woman With Obesity: Review of Bariatric Surgery
Wee
JAMA 2009;302:1097-1104.
ABSTRACT
| FULL TEXT
Iron absorption and iron status are reduced after Roux-en-Y gastric bypass
Ruz et al.
Am. J. Clin. Nutr. 2009;90:527-532.
ABSTRACT
| FULL TEXT
Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis
Sturm et al.
Eur Heart J 2009;30:2038-2043.
ABSTRACT
| FULL TEXT
Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery
The Longitudinal Assessment of Bariatric Surgery (
NEJM 2009;361:445-454.
ABSTRACT
| FULL TEXT
Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch
Aasheim et al.
Am. J. Clin. Nutr. 2009;90:15-22.
ABSTRACT
| FULL TEXT
Mitochondrial Dynamics in Mammalian Health and Disease
Liesa et al.
Physiol. Rev. 2009;89:799-845.
ABSTRACT
| FULL TEXT
Distal gastric bypass surgery for the treatment of hypothalamic obesity after childhood craniopharyngioma
Schultes et al.
Eur J Endocrinol 2009;161:201-206.
ABSTRACT
| FULL TEXT
Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus
Kirwan et al.
Am. J. Physiol. Endocrinol. Metab. 2009;297:E151-E156.
ABSTRACT
| FULL TEXT
Hormonal and Metabolic Mechanisms of Diabetes Remission after Gastrointestinal Surgery
Thaler and Cummings
Endocrinology 2009;150:2518-2525.
ABSTRACT
| FULL TEXT
Bariatric surgery does not cure all type 2 diabetes
Jadoon et al.
BMJ Case Reports 2009;2009:bcr0820080755-bcr0820080755.
ABSTRACT
| FULL TEXT
Review: Bariatric surgery: to treat diabesity
Flatt et al.
British Journal of Diabetes & Vascular Disease 2009;9:103-107.
ABSTRACT
Role of laparoscopic adjustable gastric banding in the treatment of obesity and related disorders
Singhal and Super
British Journal of Diabetes & Vascular Disease 2009;9:131-133.
ABSTRACT
Health and Functioning Among Baby Boomers Approaching 60
Martin et al.
J Gerontol B Psychol Sci Soc Sci 2009;64B:369-377.
ABSTRACT
| FULL TEXT
Bariatric Surgery and Diabetes: Who Should Be Offered the Option of Remission?
Purnell and Flum
JAMA 2009;301:1593-1595.
FULL TEXT
Anemia After Bariatric Surgery: More Than Just Iron Deficiency
von Drygalski and Andris
Nutr Clin Pract 2009;24:217-226.
ABSTRACT
| FULL TEXT
Weight Loss Surgery: Common Questions
Macias et al.
Diabetes Spectr. 2009;22:110-112.
FULL TEXT
Results of Roux-en-Y Gastric Bypass in Morbidly Obese vs Superobese Patients: Similar Body Weight Loss, Correction of Comorbidities, and Improvement of Quality of Life
Suter et al.
Arch Surg 2009;144:312-318.
ABSTRACT
| FULL TEXT
Psychiatric Evaluation and Follow-Up of Bariatric Surgery Patients
Marcus et al.
Am. J. Psychiatry 2009;166:285-291.
FULL TEXT
Pregnancy after bariatric surgery: no problem?
Gidiri and Greer
Obstet Med 2009;2:11-16.
ABSTRACT
| FULL TEXT
Impact of Different Bariatric Surgical Procedures on Insulin Action and {beta}-Cell Function in Type 2 Diabetes
Ferrannini and Mingrone
Diabetes Care 2009;32:514-520.
FULL TEXT
Laparoscopic Sleeve Gastrectomy After Gastric Banding Removal: A Feasibility Study
Frezza et al.
SURG INNOV 2009;16:68-72.
ABSTRACT
First-Phase Insulin Secretion Restoration and Differential Response to Glucose Load Depending on the Route of Administration in Type 2 Diabetic Subjects After Bariatric Surgery
Salinari et al.
Diabetes Care 2009;32:375-380.
ABSTRACT
| FULL TEXT
Human gut microbiota in obesity and after gastric bypass
Zhang et al.
Proc. Natl. Acad. Sci. USA 2009;106:2365-2370.
ABSTRACT
| FULL TEXT
Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus
Vetter et al.
ANN INTERN MED 2009;150:94-103.
ABSTRACT
| FULL TEXT
Bariatric surgery - not to be taken lightly
Taheri et al.
JRSM 2009;102:2-3.
FULL TEXT
Oral Appliance Therapy and Surgical Treatment of Obstructive Sleep Apnea
Moore
ACCP Sleep Med Brd Rev 2009;4:249-258.
FULL TEXT
REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Elangbam
Vet Pathol 2009;46:10-24.
ABSTRACT
| FULL TEXT
Reversal of Type 2 Diabetes Mellitus and Improvements in Cardiovascular Risk Factors After Surgical Weight Loss in Adolescents
Inge et al.
Pediatrics 2009;123:214-222.
ABSTRACT
| FULL TEXT
The Metabolic Syndrome
Cornier et al.
Endocr. Rev. 2008;29:777-822.
ABSTRACT
| FULL TEXT
Mechanism for Improved Insulin Sensitivity after Gastric Bypass Surgery
Bikman et al.
J. Clin. Endocrinol. Metab. 2008;93:4656-4663.
ABSTRACT
| FULL TEXT
Recommended Nutritional Supplements for Bariatric Surgery Patients
Malone
The Annals of Pharmacotherapy 2008;42:1851-1858.
ABSTRACT
| FULL TEXT
Effects of Bariatric Surgery on Cardiovascular Function
Ashrafian et al.
Circulation 2008;118:2091-2102.
FULL TEXT
Obesity and Inflammation: Lessons From Bariatric Surgery
Compher and Badellino
JPEN J Parenter Enteral Nutr 2008;32:645-647.
ABSTRACT
| FULL TEXT
Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass: An Underrecognized Cause of Irreversible Renal Failure
Nasr et al.
CJASN 2008;3:1676-1683.
ABSTRACT
| FULL TEXT
Factors Associated With Weight Loss After Gastric Bypass
Campos et al.
Arch Surg 2008;143:877-884.
ABSTRACT
| FULL TEXT
Adjustable gastric banding plus conventional therapy improved glycaemic control in obese patients with type 2 diabetes
Padwal
Evid. Based Med. 2008;13:108-108.
FULL TEXT
Obesity and the lung: 2 {middle dot} Obesity and sleep-disordered breathing
Crummy et al.
Thorax 2008;63:738-746.
ABSTRACT
| FULL TEXT
Bariatric surgery
Arterburn
BMJ 2008;337:a755-a755.
FULL TEXT
Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes
Laferrere et al.
J. Clin. Endocrinol. Metab. 2008;93:2479-2485.
ABSTRACT
| FULL TEXT
Obesity and the lung: 1 {middle dot} Epidemiology
McClean et al.
Thorax 2008;63:649-654.
ABSTRACT
| FULL TEXT
Postoperative Hypoxemia in Morbidly Obese Patients With and Without Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery
Ahmad et al.
Anesth. Analg. 2008;107:138-143.
ABSTRACT
| FULL TEXT
Surgery for obesity in adults
DTB 2008;46:41-45.
ABSTRACT
| FULL TEXT
Pharmacotherapy for obesity in menopausal women
Samat et al.
Menopause Int 2008;14:57-62.
ABSTRACT
| FULL TEXT
Increased Colorectal Epithelial Cell Proliferation and Crypt Fission Associated with Obesity and Roux-en-Y Gastric Bypass
Sainsbury et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1401-1410.
ABSTRACT
| FULL TEXT
Dietary Therapy for Obesity: An Emperor With No Clothes
Mark
Hypertension 2008;51:1426-1434.
FULL TEXT
Is there a place for bariatric surgery in treating childhood obesity?
Shield et al.
Arch. Dis. Child. 2008;93:369-372.
FULL TEXT
Happy Re-birthday: Weight Loss Surgery and the `New Me'
Throsby
Body Society 2008;14:117-133.
Obstructive Sleep Apnea: Implications for Cardiac and Vascular Disease
Lopez-Jimenez et al.
Chest 2008;133:793-804.
FULL TEXT
Body Esteem Improves After Bariatric Surgery
Madan et al.
SURG INNOV 2008;15:32-37.
ABSTRACT
Sleep Apnea and Hypertension: Interactions and Implications for Management
Kapa et al.
Hypertension 2008;51:605-608.
FULL TEXT
Obesity and Obstructive Sleep Apnea: Pathogenic Mechanisms and Therapeutic Approaches
Schwartz et al.
Proc Am Thorac Soc 2008;5:185-192.
ABSTRACT
| FULL TEXT
Vitamin status in morbidly obese patients: a cross-sectional study
Aasheim et al.
Am. J. Clin. Nutr. 2008;87:362-369.
ABSTRACT
| FULL TEXT
Surgical treatment of obesity
Bult et al.
Eur J Endocrinol 2008;158:135-145.
ABSTRACT
| FULL TEXT
Is Type 2 Diabetes an Operable Intestinal Disease?: A provocative yet reasonable hypothesis
Rubino
Diabetes Care 2008;31:S290-S296.
ABSTRACT
| FULL TEXT
Bariatric Surgery in Patients With Morbid Obesity and Type 2 Diabetes
Schernthaner and Morton
Diabetes Care 2008;31:S297-S302.
FULL TEXT
Gastrointestinal Surgery as a Treatment for Diabetes
Cummings and Flum
JAMA 2008;299:341-343.
FULL TEXT
Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association
American Diabetes Association
Diabetes Care 2008;31:S61-S78.
FULL TEXT
Duodenal Jejunal Bypass Sleeve: A Totally Endoscopic Device for the Treatment of Morbid Obesity
Gersin et al.
SURG INNOV 2007;14:275-278.
ABSTRACT
Insulin resistance and salt-sensitive hypertension in metabolic syndrome
Fujita
Nephrol Dial Transplant 2007;22:3102-3107.
FULL TEXT
Pediatric Idiopathic Intracranial Hypertension: A Review
Mercille and Ospina
Pediatr. Rev. 2007;28:e77-e86.
FULL TEXT
Spectrum and Risk Factors of Complications After Gastric Bypass
Campos et al.
Arch Surg 2007;142:969-975.
ABSTRACT
| FULL TEXT
When Policy Meets Statistics: The Very Real Effect That Questionable Statistical Analysis Has on Limiting Health Care Access for Bariatric Surgery
Livingston et al.
Arch Surg 2007;142:979-987.
ABSTRACT
| FULL TEXT
Outcomes of Preoperative Weight Loss in High-Risk Patients Undergoing Gastric Bypass Surgery
Still et al.
Arch Surg 2007;142:994-998.
ABSTRACT
| FULL TEXT
Gastric Bypass: Why Roux-en-Y? A Review of Experimental Data
Collins et al.
Arch Surg 2007;142:1000-1003.
ABSTRACT
| FULL TEXT
Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats
Guijarro et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;293:R1474-R1489.
ABSTRACT
| FULL TEXT
Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk
Parati et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;293:R1671-R1683.
ABSTRACT
| FULL TEXT
Evaluation and Management of Childhood and Adolescent Obesity
Singhal et al.
Mayo Clin Proc. 2007;82:1258-1264.
ABSTRACT
| FULL TEXT
Toward the Rational and Equitable Use of Bariatric Surgery
Flum et al.
JAMA 2007;298:1442-1444.
FULL TEXT
Long-Term Mortality after Gastric Bypass Surgery
Adams et al.
NEJM 2007;357:753-761.
ABSTRACT
| FULL TEXT
One hundred pound weight losses with an intensive behavioral program: changes in risk factors in 118 patients with long-term follow-up
Anderson et al.
Am. J. Clin. Nutr. 2007;86:301-307.
ABSTRACT
| FULL TEXT
Indirect Calorimetry: A Practical Guide for Clinicians
Haugen et al.
Nutr Clin Pract 2007;22:377-388.
ABSTRACT
| FULL TEXT
Diabetes, Weight Loss, and Sisyphus
Elasy
Clin. Diabetes 2007;25:81-82.
FULL TEXT
Bariatric Surgery for Patients With Diabetes
Eckhauser et al.
Clin. Diabetes 2007;25:83-89.
ABSTRACT
| FULL TEXT
Management of Type 2 Diabetes After Bariatric Surgery
Dunn and Jagasia
Clin. Diabetes 2007;25:112-114.
FULL TEXT
Gut Hormones, Obesity, Polycystic Ovarian Syndrome, Malignancy, and Lipodystrophy Syndromes
Bloomgarden
Diabetes Care 2007;30:1934-1939.
FULL TEXT
Case Study: A Patient With Diabetes and Weight-Loss Surgery
Cummings
Diabetes Spectr. 2007;20:173-176.
FULL TEXT
Prevalence And Trends In Obesity Among Aged And Disabled U.S. Medicare Beneficiaries, 1997-2002
Doshi et al.
Health Aff (Millwood) 2007;26:1111-1117.
ABSTRACT
| FULL TEXT
Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes
Laferrere et al.
Diabetes Care 2007;30:1709-1716.
ABSTRACT
| FULL TEXT
Bariatric Surgery for Morbid Obesity
DeMaria
NEJM 2007;356:2176-2183.
FULL TEXT
Neurologic complications of gastric bypass surgery for morbid obesity
Juhasz-Pocsine et al.
Neurology 2007;68:1843-1850.
ABSTRACT
| FULL TEXT
Malabsorption of Oral Antibiotics in Pregnancy after Gastric Bypass Surgery
Magee et al.
J Am Board Fam Med 2007;20:310-313.
ABSTRACT
| FULL TEXT
Acute Kidney Injury after Gastric Bypass Surgery
Thakar et al.
CJASN 2007;2:426-430.
ABSTRACT
| FULL TEXT
{beta}-Cell Function in Severely Obese Type 2 Diabetic Patients: Long-term effects of bariatric surgery
Camastra et al.
Diabetes Care 2007;30:1002-1004.
FULL TEXT
Bariatric Surgery in Adolescents: Recent National Trends in Use and In-Hospital Outcome
Tsai et al.
Arch Pediatr Adolesc Med 2007;161:217-221.
ABSTRACT
| FULL TEXT
Nonalcoholic Fatty Liver Disease and Obesity
Saadeh
Nutr Clin Pract 2007;22:1-10.
ABSTRACT
| FULL TEXT
Psychiatric Disorders Among Bariatric Surgery Candidates: Relationship to Obesity and Functional Health Status
Kalarchian et al.
Am. J. Psychiatry 2007;164:328-334.
ABSTRACT
| FULL TEXT
Efficacy of Gastric Bypass in the Treatment of Obesity-Related Comorbidities
Peluso and Vanek
Nutr Clin Pract 2007;22:22-28.
ABSTRACT
| FULL TEXT
Nutrition and Gastrointestinal Complications of Bariatric Surgery
Shikora et al.
Nutr Clin Pract 2007;22:29-40.
ABSTRACT
| FULL TEXT
Effect of Massive Weight Loss on Inflammatory Adipocytokines and the Innate Immune System in Morbidly Obese Women
Manco et al.
J. Clin. Endocrinol. Metab. 2007;92:483-490.
ABSTRACT
| FULL TEXT
Public Health Response to the Obesity Epidemic: Too Soon or Too Late?
Byers and Sedjo
J. Nutr. 2007;137:488-492.
ABSTRACT
| FULL TEXT
Treatment of Obesity
Thompson et al.
Mayo Clin Proc. 2007;82:93-102.
ABSTRACT
| FULL TEXT
Surgery for morbid obesity
Bennett et al.
Postgrad. Med. J. 2007;83:8-15.
ABSTRACT
| FULL TEXT
Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association
American Diabetes Association
Diabetes Care 2007;30:S48-S65.
FULL TEXT
|
